INTRODUCTION
Monitoring changes in synaptic neurotransmitter con centrations can provide insight into the neurophysio-antagonist) on the regional binding of llC-benztropine in the primate brain (papio anubis), we demonstrated that drugs acting upon either GABAergic or serotonergic neurons produce profound regional changes in acetylcholine release. These findings indicate that the mechanisms of action and the subsequent therapeutic efficacy of these centrally acting drugs may be linked to their multitransmitter effects. This application of positron emission tomography represents an extremely promising experimental approach that can be directed towards elucidating abnormalities in neurotransmitter modulation relevant to disease progression and pharmacologic treatment. INeuropsychopharmacology 8:371-376, 1993] logic mechanisms underlying the central nervous sys tem's (eNS) ability to control many biologic, behavioral, and neurohumoral processes. Upon loss of this ability, speci&c behavioral manifestations, historically attrib uted to single neurotransmitter systems, may result.
For example, Parkinson's disease (Bemheimer et al. 1973 ) and schizophrenia (Seeman et al. 1987 ) have been linked to alterations in the dopamine system and the cognitive defIcits of Alzheimer's disease (AD) have been linked to alterations in the cholinergic system (Davis and Maloney 1976; Bartus et al. 1982 Positron emission tomography (PET) is rapidly emerging as an effective imaging technique for quan titating not only cerebral metabolic rates of glucose or regional cerebral blood flow but many aspects of neu ronal physiology as well (for review, see Phelps et al. 1986 ). For example, PET has been used to monitor changes in the synaptic concentrations of the neu rotransmitters, dopamine (DA) and acetylcholine ([ACh] Dewey et al. 1990a) . Whether induced directly (Dewey et al. 1991 (Dewey et al. , 1993 or indirectly through interactions with other neurotransmitter systems (Dewey et al. 1990a (Dewey et al. , 1992a , these changes were reflected in regional de creases in the binding of either llC-benztropine (ACh) or llC-raclopride (DA) following pharmacologic ma nipulation. Gamm a-aminobutyric acid (GABA) and ser otonin (5-HT), however, have been shown to influence the release of these two neurotransmitters as well Oack son Scatton and Bartholini 1980) . Having recently demonstrated that GABA and 5-HT inhibit the release of striatal DA (Dewey et al. 1992a,b) , we ex tended these fIndings to an examination of the role that In the present study we performed paired PET scans using llC-benztropine, a muscarinic cholinergic ligand (nonselective for the muscarinic receptor sub types) whose binding characteristics have been mea sured (Dewey et al. 1990b) . The fIrst scan served as a control for the second that occurred following pretreat ment with gamma-vinyl GABA (GVG), a specifIc sui-NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.4 cide inhibitor of the GABA-catabolizing enzyme GABA transaminase ([GABA-T] EC 2.6.1.19, Schechter et al. 1977) or altanserin, a relatively selective 5-HT2 an tagonist that has recently been radiolabeled with fluorine-18 and used with PET to study the regional dis tribution of 5-HT2 receptors in the human brain (Lemaire et al. 1991) .
MATERIALS AND METHODS
Adult female baboons (Papio anubis) weighing between 13 and 18 kg were prepared for dynamic PET scanning in a Computer Technologies Imaging positron tomo graph (model 931-08/12; 15 slices, 6.5-mm slice thick ness, full width at half maximum [FWHM] , 6.0 X 6.0 mm in plane resolution). Scanning commenced at iso tope injection and continued for 84 minutes using the following scanning protocol: four scans for 15 seconds followed by two scans for 30 seconds followed by four scans for 1 minute followed by four scans for 2 minutes followed by fIve scans for 10 minutes followed by one scan for 20 minutes. Arterial blood was sampled throughout the scanning period and selected plasma samples (1.0, 5.0, 10.0, and 30.0 minutes) were analyzed for the presence of unchanged llC-benztropine as de scribed previously (Dewey et al. 1990b ). All animals, studied at the same time in their estrous cycle, were immobilized initially with ketamine (10 mg/kg, in tramuscularly) and were subsequently maintained at a constant level on gaseous anesthesia (isoflurane, n i trous oxide, and oxygen) for the duration of the stud ies. In all studies, sequential injections of llC-ben ztro pine (2.00 to 15.00 mCi, SpecifIc Activity 750 to 1500 mCi/lJ.mol), were performed on the same day. Gamma vinyl GABA was intravenously administered at a dose of 300 mg/kg 180 minutes prior to the second isotope injection (n = 3). Altanserin was intravenously ad ministered at a dose of 1.0 mg/kg 45 minutes prior to the second isotope injection (n = 3). llC-benztropine was synthesized as described previously (Dewey et aI. A refers to the control study. B refers to the second study performed 90 minutes posttreatment.
ST = striatum; FC = frontal cortex; CB = cerebellum.
NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.4 1990b). Animals remained in the tomograph between isotope injections to minimize changes in head posi tion. Movement of the animal's head during the scan ning period was also monitored with an infrared mon itoring device (Tri-Tronics, 5marteye model 5D). Vital signs and body temperature were monitored through out the scanning period and animals recovered for at least 3 weeks prior to their next study.
Regions of interest (ROJ's) were drawn directly on the PET images using software supplied with the tomo graph as detailed previously (Dewey et al. 1992b) .
Receptor availability as a function of changes in synap binding from altered radioligand delivery due to changes in regional cerebral blood flow ). We present results for the striatum, cortex, and cerebellum as well as the ratio of the striatum to the cerebellum and cortex to cerebellum, as these ratios do not contain the term K1/k2 (transport constants).
RESULTS
Imm ediately following isotope injection, radioactivity began to accumulate throughout all cortical and sub cortical gray structures. There was no accumulation of radioactivity in any white matter region. With the ex ception of the thalamus and cerebellum, which began to clear of radioactivity within 20 minutes, radioactiv ityreached a peak uptake within 60 minutes and cleared slowly over the remainder of the scanning period. This regional and temporal pattern of distribution closely paralleled our previous findings with llC-benztropine in the primate brain (Dewey et al. 1990b ). There was no detectable movement of the animal's head during
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any of the scanning procedures. Administration of GVG or altanserin did not produce changes in any of the monitored vital signs or in any animal's core tem perature, and the specihc activity of the radiotracer did not vary signihcantly within the same day. In all cases, recovery from anesthesia was umemarkable.
Regionally specihc alterations in llC-benztropine binding were observed following GVG and altanserin administration. Gamma-vinyl GAB A produced quan titative decreases in the ratio of the DV's in both the striatum (44%) and cortex (26%) but had no effect on either thalamic or cerebellar uptake (Table 1 ). In con trast, altanserin only reduced the ratio of the stria tum/cerebellum DV (32%) and had no effect on the cor tical, thalamic, or cerebellar uptake (Table 2 ). Neither GVG nor altanserin altered the rate of the systemic me tabolism of llC-benztropine or the metabolite corrected plasma input function. These decreases exceed the test/retest variability of this radio tracer performed in the same animals under identical experimental condi tions (less than 10%, Dewey et al. 1990b ).
DISCUSSION
The regional decreases we observed in radiotracer bind ing in response to pharmacologic challenge demon strate the first use of PET for noninvasively monitoring increases in the synaptic concentrations of neurotrans mitters whether induced directly (Dewey et al. 1991 (Dewey et al. , 1993 or indirectly through interactions with other func tionally linked systems (Dewey et al. 1990a (Dewey et al. , 1992b , 1992b) . This is consistent with GABA's known ability to decrease synaptic concentrations of DA (Stevens et a1. 1974) . In the present study we extended these fmdings to an examination of the roles of GABA and 5-HT in modulating ACh release in vivo. The dorsal and median raphe nucleus are the ma jor sources of 5-HT in the CNS. Serotonin-2 receptors have been localized to cortical cholinergic nerve termi nals as revealed by the loss of these receptors second ary to lesions of the nucleus basalis of Meynert (Quirion and Richard, 1985) . Serotonergic innervation to the stri atum is derived from the dorsal and medial raphe nuclei, which project to the striatum, pallidum, and sub stantia nigra (mainly the pars compacta). Serotonin has been shown to inhibit striatal ACh release (Euvrard et a1. 1977; Guyenet et a1. 1977 ) and depletion of endoge nous 5-HT increased ouabain-stimulated release of stri atal ACh (Vizi et a1. 1977) . Gillet and coworkers (1985) demonstrated that exogenously administered 5-HT, 5-HT agonists, or fluoxetine, an inhibitor of 5-HT up take, reduced striatal ACh release, whereas methyser gide, a 5-HT antagonist, increased ACh efflux in the caudal striatum (Jackson et al. 1988 ). However, Robin son (1983) found no effect of 5-HT on striatal ACh lev els but instead reported an inhibition of ACh in cortex and hippocampus.
Altanserin decreased llC-benztropine binding by 29% in the striatum (Table 2) ; although consistent with some fmdings, it is inconsistent with the fIndings of Robinson. One possible explanation may lie in the fun damental differences between the techniques used to measure neurotransmitter release and those used to in duce the changes (e.g., neurochemical lesions versus pharmacologic blockade). Following lesion of the raphe nucleus, Robinson examined ACh turnover rates in postmortem tissue by examining the slope of the fIrst order decay plots of In (ACh) versus time after the in hibition of ACh synthesis by hemicholinium-3 (HC-3). Rats were sacrifIced by microwave irradiation at 10,20, and 30 minutes following HC-3 administration. Our PET studies, however, were performed in primates in vivo by measuring decreases in the binding of II C _ benztropine in response to 5-HT2 blockade. The results of this approach, although representing the only nonin vasive methodology currently available for making quantitative measurements in the human brain, must be interpreted within the confInes of the technique. For example, a radiotracer with a low affinity (high K d) for a specifIc receptor type will be more sensitive to changes in its endogenous competitor than one with a higher affinity (low K d, Seeman et a1. 1989 ). Benztropine's K d is 4 to 7 nmollL for the muscarinic Ml and M2 site, respectively (Snyder and Yamamura 1977) . Therefore, small increases in ACh content that may have occurred following altanserin pretreatment, might not produce measurable changes in llC-benztropine binding. Fur-NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.4 thermore, unlike postmortem studies, PET measure ments are performed in live subjects. Therefore, these changes are influenced not only by the direct effects of the drug administered but also by the indirect effects the drug may have on other neurotransmitter and neu rohumoral systems. Finally, the relationship between the time of drug administration and the time and dura tion of PET scanning is extremely important. In the pres ent study, PET scanning began 45 minutes following altanserin administration and continued for 84 minutes. It is conceivable that this difference alone might explain this discrepancy as cortical increases in ACh may have occurred sooner than those in the striatum. Conversely, there may be differential time courses for compensa tory responses that regulate synaptic ACh activity for cortex and striatum.
The ventral pallidum receives direct input from ven tral striatal regions that contain a large number of GABAergic neurons (Heimer and Wilson 1975) . It is un known, however, whether this GABAergic input originates from these striatal GABAergic neurons or whether it arises from axons of other projection or GABAergic interneurons. Unlike the fIndings reported with 5-HT, GABA and GABA mimetic agents such as muscimol and SL 76 002 have been shown to produce an increase in striatal ACh content, the largest of whic h was observed in the rat striatum with smaller effects in the cortex, nucleus accumbens, olfactory tubercle, hippocampus, interpeducular nucleus, hypothalamus, and brainstem (Scatton and Bartholini, 1980) . Further more, Cosi and Wood (1988) showed a lack of GABAer gic modulation of thalamic ACh release, consistent with neuroanatomic fIndings.
Gamma-vinyl GABA produced a regionally specific decrease in II C-benztropine binding. Striatal binding decreased 47% and cortical binding decreased 28%. There were no changes observed in the thalamus or cerebellum. These regional and quantitative changes are consistent with GABA's reported excitatory role in striatal and cortical ACh release (Scatton and Bartholin i , 1980; Bonanno and Raiteri, 1988) . Taken with our previ ous work using llC-raclopride and GVG (Dewey, et al., 1992b) , this study represents the fIrst demonstra tion with PET that a single drug (GVG), within the sa me timeframe, can produce opposite effects in different neurotransmitter systems within the same animal. SpecifIcally, GVG administration increased llC-raclo pride binding and decreased llC-benztropine binding.
These data support the use of PET, not only for monitoring changes in synaptic neurotransmitter con centrations, but also for assessing the multiple mecha nisms of action of new and potentially useful centrally acting therapeutic drugs. These fIndings have implica tions for the pathophysiology and pharmacotherapy of disease states that have classically been defIned as neu rotransmitter specifIc in origin. SpecifIcally, we can use this application of PET as a tool to determine whether the ability of a neurotransmitter to modulate the activ it y of another functionally linked neurotransmitter is involved in the disease process. By capitalizing on our knowledge concerning neurotransmitter interactions, this would have direct implications for treatment in that therapeutic efficacy could be achieved by indirectly, rather than directly, altering neurotransmitter activity. Potential treatments could be developed for choliner g i c, dopaminergic, thermore, this information may be used to predict the potential side effects of pharmacologic treatment.
An example of a relevant application of this ap proach is to the study of AD. AD has classically been characterized by a cortical cholinergic deficit. The majority of drug trials have used therapeutic agents (e.g., cholinergic agonists and cholinesterase inhibitors) that were designed to directly reverse this deficiency. With few exceptions, these drugs have not been effica cious. Our PET data suggest that both serotonergic blockade and GABA potentiation may represent two new alternative pharmacologic strategies for enhanc ing cholinergic activity. Conversely, agents that en hance or decrease serotonergic and GABA activity, respectively, should be used with caution in such pa ti ents, as these may produce cholinergic hypofunction resulting in further cognitive impairment. At the level of pathophysiologic mechanisms, the application of the approach described here may be used to characterize the progression of AD. For example, human studies can be designed to address the effects of chronic choliner gic depletion on other functionally linked neurotrans mitters putatively involved in other symptomatology of the disease (e.g., psychiatric features). Finally, the efficacy of atypical neuroleptics and benzodiazepine agonists for treating symptoms in schizophrenia may be linked to the ability of these compounds to block serot onergic receptors and increase GABA activity, respectively. Consistent with our findings, such treat ment would result in an increase in cholinergic activity and might be beneficial if cholinergic hypofunction un derlies these symptoms, as has been suggested (Tan don and Greden, 1989) . Future PET studies will be directed toward addressing such issues in the patho phYSiology and treatment of neuropsychiatric disease.
